Atyr Pharma Inc
ATYR
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.19B
Close$
$-0.02
103.9% downside
Current Fair Value
103.9% downsideOvervalued by 103.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.19 Billion |
|---|---|
| Enterprise Value | $1.19 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.8 |
| Beta | 0.66 |
| Outstanding Shares | 98,043,839 |
Return
| Return on Equity | -120.88% |
|---|---|
| Return on Assets | -87.92% |
| Return on Invested Capital | -108.42% |
Valuation & Multiples
| P/E Ratio | -0.76 |
|---|---|
| PEG | 2.76 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 6276.44 |
| Enterprise Value to EBIT | -16.19 |
| Enterprise Value to Net Income | -18 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.2 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 15, 2026
EPS Estimate
$-0.16
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Atyr Pharma Inc
80 employees
CEO: Sanjay Shukla atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological ...